Biotech · Public company · Florham Park, NJ, US
Cellectar Biosciences, Inc.
Ticker CLRB · SEC CIK 0001279704
Track this companyFree. Adds Cellectar Biosciences, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials84 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline13
- CarboplatinPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- NOV-002Phase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Iopofosine I 131 fractionated dosePhase 2 · Waldenstrom MacroglobulinemiaClinicalTrials.gov · fetched Nov 12, 2026
- Iopofosine I 131 multiple dosePhase 2 · Waldenstrom MacroglobulinemiaClinicalTrials.gov · fetched Nov 12, 2026
- Iopofosine I 131 single dosePhase 2 · Waldenstrom MacroglobulinemiaClinicalTrials.gov · fetched Nov 12, 2026
- NOV-205Phase 2 · Hepatitis CClinicalTrials.gov · fetched Nov 12, 2026
- CLR 125Phase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- CLR 131Phase 1 · High-Grade GliomaClinicalTrials.gov · fetched Nov 12, 2026
- CLR 131Phase 1 · Pediatric Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- dexamethasonePhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- I-131-CLR1404Phase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- Iopofosine I 131Phase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Phase 1 Study of CLR 125 in Triple Negative Breast CancerPHASE1 · RECRUITING · started Dec 5, 2025ClinicalTrials.gov NCT07311993 · fetched Nov 12, 2026
- Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGGPHASE1 · ACTIVE_NOT_RECRUITING · started Oct 1, 2023ClinicalTrials.gov NCT05610891 · fetched Nov 12, 2026
- CLR 131 Combined With Radiation for Head and Neck CancerPHASE1 · COMPLETED · started Dec 20, 2019ClinicalTrials.gov NCT04105543 · fetched Nov 12, 2026
- Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 30, 2019ClinicalTrials.gov NCT03478462 · fetched Nov 12, 2026
- Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromPHASE2 · ACTIVE_NOT_RECRUITING · started Jul 26, 2017ClinicalTrials.gov NCT02952508 · fetched Nov 12, 2026
- Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple MyelomaPHASE1 · COMPLETED · started Feb 1, 2015ClinicalTrials.gov NCT02278315 · fetched Nov 12, 2026
- A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard TherapyPHASE2 · COMPLETED · started Mar 1, 2010ClinicalTrials.gov NCT01058512 · fetched Nov 12, 2026
- Study of NOV-002 in Combination With Chemotherapy to Treat Lung CancerPHASE3 · COMPLETED · started Nov 1, 2006ClinicalTrials.gov NCT00347412 · fetched Nov 12, 2026
SEC filings12
- 8-K · FORM 8-KSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 10, 2026 · fetched Nov 12, 2026
- S-1/A · FORM S-1/ASEC EDGAR · filed May 29, 2026 · fetched Nov 12, 2026
- S-1 · FORM S-1SEC EDGAR · filed May 19, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 18, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 8, 2026 · fetched Nov 12, 2026
- 10-K/A · 10-K/ASEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026